Journal of Clinical & Experimental OncologyISSN: 2324-9110

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Clin Exp Oncol Vol: 6 Issue: 3

Antiangiogenic Activity of rTRAIL is Potentiated by Sflt-1, a VEGF Trap

Yashaswini B, Adel Mutahar and Bharathi P Salimath*

Department of Studies in Biotechnology, Molecular Oncology Lab, University of Mysore, Manasagangotri, Mysore, Karnataka, India

*Corresponding Author : Bharathi P Salimath
Department of Studies in Biotechnology, Molecular Oncology Lab, University of Mysore, Manasagangotri, Mysore, Karnataka, India
Tel: 0821-2419879
E-mail: [email protected]

Received: March 31, 2017 Accepted: April 13, 2017 Published: April 20, 2017

Citation: Yashaswini B, Adel Mutahar, Bharathi P Salimath (2017) Antiangiogenic Activity of rTRAIL is Potentiated by Sflt-1, a VEGF Trap. J Clin Exp Oncol 6:3. doi: 10.4172/2324-9110.1000185

Abstract

Objective: Anti-angiogenesis and pro-apoptosis are the two processes which are strategically used to target tumors. The soluble form of VEGF receptor 1 (Flt-1) is a modulator of VEGF activity and could be useful as a trap to intrinsically sequester VEGF in tumor cells. In the present study, we have investigated the role of rTRAIL in inhibiting VEGF-mediated angiogenesis and its synergistic potentiation by sFlt-1.

Methods: We have expressed human recombinant TRAIL, to study its role in anti-angiogenesis and a 2-domain active variant of sFlt-1 by bacterial expression to be used as a trap for VEGF. 3[H] thymidine incorporation assay was used to confirm the inhibitory activity of sFlt-1 and/or rTRAIL on cell proliferation. The synergistic anti-migratory and anti-angiogenic activity of sFlt-1 and rTRAIL were assessed using endothelial cell wound healing and tube formation assay in-vitro and by rat corneal micropocket assay in-vivo.

Results: Inhibition of cell proliferation was evident in sFlt-1 and rTRAIL treated cells in a dose -dependent manner with more than 60% reduction in proliferation rate as compared to the tumor cells treated with sFlt-1 and rTRAIL alone. Furthermore, the anti-metastatic and anti-angiogenic activity of sFlt-1 and rTRAIL in combination was evident in endothelial wound healing and tube formation with a significant reduction in the number of cells migrated into the wounded area and the number of honey comb-like structures with the length of the tubes formed to mimic blood vessel formation in-vitro respectively. The in-vivo corneal micropocket assay confirmed the anti-angiogenic effect of sFlt-1 and rTRAIL in combination.

Conclusion: The synergistic role of sFlt-1 and rTRAIL as the potential inhibitors of VEGF- mediated angiogenesis could be therapeutically exploited.

Keywords: Angiogenesis; rTRAIL; Soluble Flt-1

Track Your Manuscript

Share This Page

Media Partners